Proliferative Suppression by CDK4/6 Inhibition

Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells

Dayana B. Rivadeneira, Christopher N. Mayhew, Chellappagounder Thangavel, Elena Sotillo, Christopher A. Reed, Xavier Graña, Erik S. Knudsen

Research output: Contribution to journalArticle

71 Citations (Scopus)

Abstract

Background & Aims: Hepatocellular carcinoma is the third leading cause of cancer mortality worldwide; current chemotherapeutic interventions for this disease are largely ineffective. The retinoblastoma tumor suppressor (RB) is functionally inactivated at relatively high frequency in hepatocellular carcinoma and hepatoma cell lines. Here, we analyzed the ability of CDK4/6 inhibition to inhibit hepatocyte proliferation and the effect of RB status on this process. Methods: Hepatoma cell lines and xenograft models harboring RB knockdown and mice harboring liver-specific Rb deletion were used to define the role of RB function in response to CDK4/6 inhibition. Results: Our study shows that CDK4/6-dependent cell cycle progression in hepatoma cells was readily arrested by inhibition of CDK4/6 by PD-0332991 or p16ink4a irrespective of RB status. Interestingly, upon CDK4/6 inhibition, p107 protein stability was dramatically increased as a function of RB loss. This engagement of compensatory mechanisms was critical for cell cycle inhibition in the absence of RB, because both the E1A oncoprotein and overexpression of E2F proteins were capable of overcoming the effect of CDK4/6 inhibition. These findings were recapitulated in xenograft models. Furthermore, to determine how these findings relate to hepatocyte proliferation in vivo, mice were exposed to carbon tetrachloride to induce liver regeneration followed by treatment with PD-0332991. This treatment significantly inhibited hepatocyte proliferation. Strikingly, this facet of PD-0332991 function was retained even in RB-deficient livers. Conclusions: These data show that CDK4/6 inhibition is a potent mediator of cytostasis and that RB loss can be readily compensated for in the context of both hepatoma cell lines and liver tissue.

Original languageEnglish (US)
JournalGastroenterology
Volume138
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Retinoblastoma
Hepatocellular Carcinoma
Liver
Hepatocytes
Heterografts
Cell Line
Cell Cycle
E2F Transcription Factors
Liver Regeneration
Carbon Tetrachloride
Protein Stability
Oncogene Proteins
Neoplasms
Mortality
palbociclib

Keywords

  • CDK4/6 Inhibitor
  • HCC
  • Hepatocellular Carcinoma
  • Retinoblastoma Tumor Suppressor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Proliferative Suppression by CDK4/6 Inhibition : Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells. / Rivadeneira, Dayana B.; Mayhew, Christopher N.; Thangavel, Chellappagounder; Sotillo, Elena; Reed, Christopher A.; Graña, Xavier; Knudsen, Erik S.

In: Gastroenterology, Vol. 138, No. 5, 05.2010.

Research output: Contribution to journalArticle

Rivadeneira, Dayana B. ; Mayhew, Christopher N. ; Thangavel, Chellappagounder ; Sotillo, Elena ; Reed, Christopher A. ; Graña, Xavier ; Knudsen, Erik S. / Proliferative Suppression by CDK4/6 Inhibition : Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells. In: Gastroenterology. 2010 ; Vol. 138, No. 5.
@article{29f4905ea3da4453b958d9cba6f2b44c,
title = "Proliferative Suppression by CDK4/6 Inhibition: Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells",
abstract = "Background & Aims: Hepatocellular carcinoma is the third leading cause of cancer mortality worldwide; current chemotherapeutic interventions for this disease are largely ineffective. The retinoblastoma tumor suppressor (RB) is functionally inactivated at relatively high frequency in hepatocellular carcinoma and hepatoma cell lines. Here, we analyzed the ability of CDK4/6 inhibition to inhibit hepatocyte proliferation and the effect of RB status on this process. Methods: Hepatoma cell lines and xenograft models harboring RB knockdown and mice harboring liver-specific Rb deletion were used to define the role of RB function in response to CDK4/6 inhibition. Results: Our study shows that CDK4/6-dependent cell cycle progression in hepatoma cells was readily arrested by inhibition of CDK4/6 by PD-0332991 or p16ink4a irrespective of RB status. Interestingly, upon CDK4/6 inhibition, p107 protein stability was dramatically increased as a function of RB loss. This engagement of compensatory mechanisms was critical for cell cycle inhibition in the absence of RB, because both the E1A oncoprotein and overexpression of E2F proteins were capable of overcoming the effect of CDK4/6 inhibition. These findings were recapitulated in xenograft models. Furthermore, to determine how these findings relate to hepatocyte proliferation in vivo, mice were exposed to carbon tetrachloride to induce liver regeneration followed by treatment with PD-0332991. This treatment significantly inhibited hepatocyte proliferation. Strikingly, this facet of PD-0332991 function was retained even in RB-deficient livers. Conclusions: These data show that CDK4/6 inhibition is a potent mediator of cytostasis and that RB loss can be readily compensated for in the context of both hepatoma cell lines and liver tissue.",
keywords = "CDK4/6 Inhibitor, HCC, Hepatocellular Carcinoma, Retinoblastoma Tumor Suppressor",
author = "Rivadeneira, {Dayana B.} and Mayhew, {Christopher N.} and Chellappagounder Thangavel and Elena Sotillo and Reed, {Christopher A.} and Xavier Gra{\~n}a and Knudsen, {Erik S.}",
year = "2010",
month = "5",
doi = "10.1053/j.gastro.2010.01.007",
language = "English (US)",
volume = "138",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Proliferative Suppression by CDK4/6 Inhibition

T2 - Complex Function of the Retinoblastoma Pathway in Liver Tissue and Hepatoma Cells

AU - Rivadeneira, Dayana B.

AU - Mayhew, Christopher N.

AU - Thangavel, Chellappagounder

AU - Sotillo, Elena

AU - Reed, Christopher A.

AU - Graña, Xavier

AU - Knudsen, Erik S.

PY - 2010/5

Y1 - 2010/5

N2 - Background & Aims: Hepatocellular carcinoma is the third leading cause of cancer mortality worldwide; current chemotherapeutic interventions for this disease are largely ineffective. The retinoblastoma tumor suppressor (RB) is functionally inactivated at relatively high frequency in hepatocellular carcinoma and hepatoma cell lines. Here, we analyzed the ability of CDK4/6 inhibition to inhibit hepatocyte proliferation and the effect of RB status on this process. Methods: Hepatoma cell lines and xenograft models harboring RB knockdown and mice harboring liver-specific Rb deletion were used to define the role of RB function in response to CDK4/6 inhibition. Results: Our study shows that CDK4/6-dependent cell cycle progression in hepatoma cells was readily arrested by inhibition of CDK4/6 by PD-0332991 or p16ink4a irrespective of RB status. Interestingly, upon CDK4/6 inhibition, p107 protein stability was dramatically increased as a function of RB loss. This engagement of compensatory mechanisms was critical for cell cycle inhibition in the absence of RB, because both the E1A oncoprotein and overexpression of E2F proteins were capable of overcoming the effect of CDK4/6 inhibition. These findings were recapitulated in xenograft models. Furthermore, to determine how these findings relate to hepatocyte proliferation in vivo, mice were exposed to carbon tetrachloride to induce liver regeneration followed by treatment with PD-0332991. This treatment significantly inhibited hepatocyte proliferation. Strikingly, this facet of PD-0332991 function was retained even in RB-deficient livers. Conclusions: These data show that CDK4/6 inhibition is a potent mediator of cytostasis and that RB loss can be readily compensated for in the context of both hepatoma cell lines and liver tissue.

AB - Background & Aims: Hepatocellular carcinoma is the third leading cause of cancer mortality worldwide; current chemotherapeutic interventions for this disease are largely ineffective. The retinoblastoma tumor suppressor (RB) is functionally inactivated at relatively high frequency in hepatocellular carcinoma and hepatoma cell lines. Here, we analyzed the ability of CDK4/6 inhibition to inhibit hepatocyte proliferation and the effect of RB status on this process. Methods: Hepatoma cell lines and xenograft models harboring RB knockdown and mice harboring liver-specific Rb deletion were used to define the role of RB function in response to CDK4/6 inhibition. Results: Our study shows that CDK4/6-dependent cell cycle progression in hepatoma cells was readily arrested by inhibition of CDK4/6 by PD-0332991 or p16ink4a irrespective of RB status. Interestingly, upon CDK4/6 inhibition, p107 protein stability was dramatically increased as a function of RB loss. This engagement of compensatory mechanisms was critical for cell cycle inhibition in the absence of RB, because both the E1A oncoprotein and overexpression of E2F proteins were capable of overcoming the effect of CDK4/6 inhibition. These findings were recapitulated in xenograft models. Furthermore, to determine how these findings relate to hepatocyte proliferation in vivo, mice were exposed to carbon tetrachloride to induce liver regeneration followed by treatment with PD-0332991. This treatment significantly inhibited hepatocyte proliferation. Strikingly, this facet of PD-0332991 function was retained even in RB-deficient livers. Conclusions: These data show that CDK4/6 inhibition is a potent mediator of cytostasis and that RB loss can be readily compensated for in the context of both hepatoma cell lines and liver tissue.

KW - CDK4/6 Inhibitor

KW - HCC

KW - Hepatocellular Carcinoma

KW - Retinoblastoma Tumor Suppressor

UR - http://www.scopus.com/inward/record.url?scp=77951679998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951679998&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2010.01.007

DO - 10.1053/j.gastro.2010.01.007

M3 - Article

VL - 138

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -